Skip to content

InterCure to receive 230 million shekels in war-damage compensation

A settlement larger than the company's market value • 129 million shekels still to be paid

InterCure announced on Monday, 24 August 2026, that it had reached a final settlement with the Israel Tax Authority and the compensation fund on its claim for compensation for indirect damage caused by the 7 October 2023 attack and the war that followed. The cumulative compensation was set at 230 million shekels, about $77 million. Trading in the company's share in Tel Aviv was halted before the publication and resumed afterwards. Trading on Nasdaq had already been halted on the previous Friday.

Indirect damage is not the physical damage to buildings and equipment. It is the lost profits of a business that could not operate. The main growing and production farm of Canndoc, InterCure's subsidiary, is at Kibbutz Nir Oz. It was badly hit on 7 October, two of its employees were kidnapped to Gaza, and the area around it was defined for a long period as a closed military zone.

The sum is larger than the market value of the entire company, but it is also a compromise: the claim InterCure filed stood at more than 300 million shekels, meaning it gave up about 70 million. Of the 230 million, 101 million had already been received as advances, so the remaining payment stands at about 129 million shekels.

What exactly was agreed, and how much money actually comes in

The remaining payment is the figure that matters to the company itself. At the end of 2025 InterCure had 46.5 million shekels in cash and cash equivalents, compared with 78.3 million a year earlier, and total liabilities of 294 million shekels, of which about 148 million were short-term and long-term loans. In other words, the money not yet received is by itself equal to about 87% of the financial debt with which it ended the previous year.

From claim to settlement: InterCure's indirect-damage compensation for the 7 October attack and the war. Final settlement with the Tax Authority and the compensation fund, 24 August 2026.

  • The claim filed: more than 300 million shekels.
  • The settlement signed: 230 million shekels.
  • The gap: about 70 million shekels, or 23% less.
  • Of the 230 million, 101 million already paid as advances, about 129 million still expected.

The settlement, about $77 million, was larger than InterCure's market value on the eve of the announcement, about $51 million, but about 70 million shekels lower than the claim that was filed. (Data: the company announcement, 24 August 2026; market value according to the Nasdaq share price in the days before the announcement.)

By way of comparison, InterCure's market value on Nasdaq in the days before the announcement stood at about $51 million, about a third lower than the size of the settlement. That is one of the signs that this is an exceptional event in its scale relative to the company, not a routine update.

One figure still needs clarification. In its annual report for 2025 the company reported a total damages claim of 251 million shekels and advances received of 82 million, while the announcement refers only to an indirect-damage claim of more than 300 million and advances of 101 million. InterCure noted in the report that the claim was not final and could grow. The announcement also does not say what became of the direct-damage component, which is not included in the settlement.

The compensation has already been holding up the accounts

The money from the compensation fund is not only a future cash injection. For two years it has already been a central component in the company's reported results. An analysis published of the first-half 2025 accounts noted that InterCure's accounting operating profit fell from 10.5 million shekels to 5.7 million, mainly under the influence of the lower compensation received in that period: 9 million shekels, compared with 16.5 million in the same half of the previous year.

That is also why the adjusted EBITDA measure the company tends to highlight strips out the compensation: it is meant to show what is happening in the business itself, without the money from the state. In 2025 InterCure recorded revenues of 270.2 million shekels, a rise of 13% compared with 2024, and positive cash flow from current operations of 16.8 million shekels. In the same year it also recorded an operating loss of 27.2 million and a total loss of 36.8 million shekels.

What this means for growing in Israel

In the announcement the company said it intends to accelerate the rehabilitation of the Nir Oz facility and return it to full activity «as soon as possible», and that the rehabilitated facility is supposed to strengthen production capacity and support supply to Germany's growing medical-cannabis market. The company's CEO and chairman, Alex Rabinovich, said InterCure was «moving from recovery back to growth».

In the annual report for 2025 the company itself wrote that the rehabilitation process was running longer than planned, and that it was now focusing on rehabilitating the genetics bank. In the meantime, Canndoc's return to Israeli pharmacy shelves has relied mainly on other sources: since May 2026 it has been importing the Totem brand, grown in Canada, and the Israeli output it markets under the American brand The Flowery is grown at a Ganja Geek facility in moshav Herut, not on the farm it owns. Its second farm, at Kibbutz Beit HaEmek, is much smaller, and there are people in the industry who estimate that it is on the way to closure.

There is also a warning sign from the recent past. When activity at Nir Oz was renewed in the first half of 2025, it actually squeezed margins: cost of goods sold rose more than revenues, and gross profit fell to about 38.5 million shekels. A return to full production does not automatically translate into profitability.

The background the announcement does not mention

The settlement was published on the day a 1-for-5 reverse share split at InterCure took effect, intended to lift the share price above the one-dollar threshold and help the company meet Nasdaq listing requirements. That same day also ended the 180-day compliance period the U.S. exchange had given it, and according to the company's notice of 19 August it expected to receive a delisting determination from Nasdaq staff and intended to appeal.

There is no declared link in the announcement between the two moves, and it cannot be inferred that the settlement was intended to serve the listing process. It does change the financial picture with which the company approaches the appeal. In the announcement itself InterCure describes itself as the «most profitable and fastest-growing» cannabis company outside North America, a description that is hard to reconcile with the total loss it recorded in 2025.

The money comes from a public fund

The compensation is paid from the compensation fund, which is administered at the Tax Authority and financed mainly from a set-aside of part of the purchase-tax collection. According to figures the authority presented to the Knesset Finance Committee, about 22 billion shekels have been paid from the fund for indirect damage, in the framework of about 824,000 claims filed since the start of the war. A settlement of 230 million shekels for one company is about one percent of the total amount paid for indirect damage.

Nir Oz is among the communities that were evacuated, whose claims are handled on a track that allows compensation for the actual damage without caps set in advance, a track in which the large claims that remain open in the fund are concentrated.

Enjoyed this article? Add us on GoogleTo see more from Cannabis Magazine in your search results (opens in new tab)